Literature DB >> 20449778

[Urinary tract infections and antibiotic resistance].

P Heisig1.   

Abstract

Urinary tract infections (UTI) usually are monoinfections caused by the endogenous microflora including gram-negatives, such as Escherichia coli, or gram-positives, like enterococci. This allows for an empiric treatment of uncomplicated UTIs and a short duration of therapy to minimize the probability for the development of resistance. Resistance often is based upon mutations altering the drug target (sulfonamides, trimethoprim, fluoroquinolones, fosfomycin) or acquisition of resistance genes (beta-lactams). The latter can be collocated with other resistance genes on mobile genetic elements mediating multiple drug resistance. Such elements are part of the chromosome of the Escherichia coli clonal group A (cgA). The prevalence of resistance to nitrofurantoin and fosfomycin is below 6%, while that of sulfonamide/trimethoprim varies between 15 and 50% all over Europe. Resistance to fluoroquinolones and amoxycillin approximates 15 and over 30%, respectively. A value of >20% for the empiric treatment of uncomplicated UTIs is associated with a significantly increased duration of therapy suggesting alternative antibiotic regimens.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20449778     DOI: 10.1007/s00120-010-2259-y

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  17 in total

Review 1.  Inhibitors of bacterial topoisomerases: mechanisms of action and resistance and clinical aspects.

Authors:  P Heisig
Journal:  Planta Med       Date:  2001-02       Impact factor: 3.352

2.  Redefining extended-spectrum beta-lactamases: balancing science and clinical need.

Authors:  Christian G Giske; Arnfinn S Sundsfjord; Gunnar Kahlmeter; Neil Woodford; Patrice Nordmann; David L Paterson; Rafael Cantón; Timothy R Walsh
Journal:  J Antimicrob Chemother       Date:  2008-10-28       Impact factor: 5.790

Review 3.  Type II topoisomerases--inhibitors, repair mechanisms and mutations.

Authors:  Peter Heisig
Journal:  Mutagenesis       Date:  2009-09-17       Impact factor: 3.000

4.  Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA).

Authors:  George G Zhanel; Tamiko L Hisanaga; Nancy M Laing; Melanie R DeCorby; Kim A Nichol; Barb Weshnoweski; Jack Johnson; Ayman Noreddin; Don E Low; James A Karlowsky; Daryl J Hoban
Journal:  Int J Antimicrob Agents       Date:  2006-05-18       Impact factor: 5.283

5.  Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction.

Authors:  V I Enne; D M Livermore; P Stephens; L M Hall
Journal:  Lancet       Date:  2001-04-28       Impact factor: 79.321

6.  Epidemiology of urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.

Authors:  Javier Ena; Francisco Arjona; Carmen Martínez-Peinado; Maria Del Mar López-Perezagua; Concepción Amador
Journal:  Urology       Date:  2006-12       Impact factor: 2.649

7.  An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project.

Authors:  G Kahlmeter
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

Review 8.  Urinary tract infections.

Authors:  Dimitri M Drekonja; James R Johnson
Journal:  Prim Care       Date:  2008-06       Impact factor: 2.907

Review 9.  Plasmid-mediated quinolone resistance: a multifaceted threat.

Authors:  Jacob Strahilevitz; George A Jacoby; David C Hooper; Ari Robicsek
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

10.  A module located at a chromosomal integration hot spot is responsible for the multidrug resistance of a reference strain from Escherichia coli clonal group A.

Authors:  Mathilde Lescat; Alexandra Calteau; Claire Hoede; Valérie Barbe; Marie Touchon; Eduardo Rocha; Olivier Tenaillon; Claudine Médigue; James R Johnson; Erick Denamur
Journal:  Antimicrob Agents Chemother       Date:  2009-04-13       Impact factor: 5.191

View more
  2 in total

1.  [Transrectal prostate biopsy: effective anesthesia, complications, and influence on clinical outcome after radical prostatectomy].

Authors:  G Müller; H Borrusch; I Knop; U Otto
Journal:  Urologe A       Date:  2011-04       Impact factor: 0.639

Review 2.  Role of D-mannose in urinary tract infections - a narrative review.

Authors:  Reeta Ala-Jaakkola; Arja Laitila; Arthur C Ouwehand; Liisa Lehtoranta
Journal:  Nutr J       Date:  2022-03-22       Impact factor: 3.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.